From the ASX release of 2 November 2018 announcing the Ikon judgement decision:
“Cellmid has already expensed its legal costs to date in the relevant financial years and made an allowance, and noted it as a contingent liability, regarding this matter in its 2018 financial accounts.”
Ann: Appendix 4C and Notes to Appendix 4C, page-44
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
